drugset / Trial / NCT00080197

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

NCT00080197

Phase 2 Completed 250 enrolled Eisai Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if E7070 is an efficacious, safe, and tolerable treatment for patients with metastatic breast cancer who have failed, or could not tolerate, prior treatments with an anthracycline, a taxane, and capecitabine.

Timeline

Start
2004-02
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject indisulam Small molecule